A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release (PR) in Patients with Early Stage Parkinson's Disease

Kelly L. Sullivan

A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release (PR) in Patients with Early Stage Parkinson's Disease

Biostatistics, Epidemiology & Environmental Health Sciences

Research output: Other contribution › Other

Original language	American English
State	Published - 2012

Disciplines

Epidemiology
Public Health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@misc{169edc04eccb4279841de4b6a9793733,

title = "A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release (PR) in Patients with Early Stage Parkinson's Disease",

author = "Sullivan, {Kelly L.}",

note = "Kelly L. Sullivan (Coordinator), {"}A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release (PR) in Patients with Early Stage Parkinson's Disease,{"} GlaxoSmithKline. (2012-present).",

year = "2012",

language = "American English",

type = "Other",

}

TY - GEN

T1 - A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release (PR) in Patients with Early Stage Parkinson's Disease

AU - Sullivan, Kelly L.

N1 - Kelly L. Sullivan (Coordinator), "A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release (PR) in Patients with Early Stage Parkinson's Disease," GlaxoSmithKline. (2012-present).

PY - 2012

Y1 - 2012

UR - https://clinicaltrials.gov/ct2/show/NCT01485172

M3 - Other

ER -

A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release (PR) in Patients with Early Stage Parkinson's Disease

Disciplines

UN SDGs

Other files and links

Cite this